Stock Track | Biogen's Stock Plummets 6.5% as Weak 2025 Outlook Overshadows Alzheimer's Drug Strength

Stock Track

Feb 12, 2025

Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.

The Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its core multiple sclerosis drugs as key headwinds.

Despite the disappointing guidance, Biogen reported some encouraging signs in its fourth-quarter earnings report. Sales of Leqembi, which it co-developed with Japan's Eisai Co., Ltd., reached $87 million for the quarter, surpassing analysts' expectations of $67 million. The company also announced a collaboration with Royalty Pharma to provide up to $250 million in research and development funding for its potential lupus treatment litifilimab.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1176170990"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176170990\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176170990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176170990","market":"us","top_or_hot":-1,"title":"Stock Track | Biogen's Stock Plummets 6.5% as Weak 2025 Outlook Overshadows Alzheimer's Drug Strength","media":"Stock Track","content":"<p>Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.</p>\n\n<p>The Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its core multiple sclerosis drugs as key headwinds.</p>\n\n<p>Despite the disappointing guidance, Biogen reported some encouraging signs in its fourth-quarter earnings report. Sales of Leqembi, which it co-developed with Japan's Eisai Co., Ltd., reached $87 million for the quarter, surpassing analysts' expectations of $67 million. The company also announced a collaboration with Royalty Pharma to provide up to $250 million in research and development funding for its potential lupus treatment litifilimab.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Biogen's Stock Plummets 6.5% as Weak 2025 Outlook Overshadows Alzheimer's Drug Strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Biogen's Stock Plummets 6.5% as Weak 2025 Outlook Overshadows Alzheimer's Drug Strength\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-12 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.</p>\n\n<p>The Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its core multiple sclerosis drugs as key headwinds.</p>\n\n<p>Despite the disappointing guidance, Biogen reported some encouraging signs in its fourth-quarter earnings report. Sales of Leqembi, which it co-developed with Japan's Eisai Co., Ltd., reached $87 million for the quarter, surpassing analysts' expectations of $67 million. The company also announced a collaboration with Royalty Pharma to provide up to $250 million in research and development funding for its potential lupus treatment litifilimab.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BIIB","symbol_name":"渤健公司","start_time":0,"source_url":"","article_id":"1176170990","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176170990","pubTimestamp":1739371440,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.The Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BIIB":"渤健公司"},"translate_title":"股票轨迹百健(Biogen)股价暴跌6.5%，2025年前景疲软掩盖了阿尔茨海默病药物的实力","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BIIB":1},"content_text":"Biogen Inc.'s stock plummeted over 6.5% in pre-market trading on Wednesday as the biotech company provided a lackluster profit outlook for 2025, overshadowing better-than-expected sales of its newly launched Alzheimer's drug Leqembi.\nThe Cambridge, Massachusetts-based drugmaker forecast adjusted earnings per share for 2025 to range between $15.25 and $16.25, falling short of analysts' average estimate of $16.34. Biogen cited the impact of a strong U.S. dollar and intensifying competition for its core multiple sclerosis drugs as key headwinds.\nDespite the disappointing guidance, Biogen reported some encouraging signs in its fourth-quarter earnings report. Sales of Leqembi, which it co-developed with Japan's Eisai Co., Ltd., reached $87 million for the quarter, surpassing analysts' expectations of $67 million. The company also announced a collaboration with Royalty Pharma to provide up to $250 million in research and development funding for its potential lupus treatment litifilimab.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}